Overview: Factor VII Functional TestIntroduction: The Factor VII Functional Test measures factor VII activity to diagnose clotting disorders, causing excessive bleeding. Following 2023 ASH guidelines, it uses a clotting assay for high specificity, aiding in coagulation screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in coagulation for patients with suspected bleeding disorders.
Other Names: Factor VII Assay, Proconvertin Activity Test.
FDA Status: Laboratory-developed test (LDT), meeting coagulation standards for diagnostic accuracy.
Historical Milestone: Factor VII testing began in the 1950s with coagulation research. Functional assays emerged in the 1970s, and by the 2000s, standardized clotting assays improved accuracy.
Purpose: Diagnoses clotting disorders, guides factor replacement therapy, and monitors factor VII activity in patients with excessive bleeding.
Test Parameters: 1. Factor VII Activity
Pretest Condition: No fasting required. Collect plasma at any time. Report symptoms like excessive bleeding, and list medications like factor concentrates.
Specimen: 2-4 mL plasma (NaCit). Centrifuge within 1 hour. Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document excessive bleeding or history of clotting disorders. Include current medications, especially factor concentrates.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for factor replacement therapy.
Procedural Considerations: Uses a clotting assay to measure factor VII activity. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Factor concentrates or improper storage can affect results. Hemolysis may reduce accuracy.
Clinical Significance: Low factor VII activity suggests bleeding disorders, prompting factor replacement therapy. Normal activity may require further testing.
Specialist Consultation: Consult a hematologist for result interpretation.
Additional Supporting Tests: PT/INR, factor VII mutation test, or bleeding time to confirm bleeding disorders.
Test Limitations: Results may be affected by recent factor therapy. Clinical correlation is required.
References: ASH Hemophilia Guidelines, 2023; Blood, Peyvandi F, 2022.
